AMRI

3Q Revenues: $60.8 million (+9%)

3Q Earnings: $3.9 million (loss of $2.1 million 3Q12)

YTD Revenues: $179.5 million (+13%)

YTD Earnings: $8.2 million (loss of $5.7 million YTD12)

Comments: Total contract revenue in the quarter was $53.0 million, up 16% and includes AMRI’s Discovery Services ($10.4 million, +17%), Development and Small Scale Manufacturing ($9.0 million, +22%), and Large Scale Manufacturing ($33.6 million, +15%). Royalty revenue in the quarter was $7.7 million, down 18% and includes royalties from Allegra products, as well as $2.0 million from certain amphetamine salts sold by Actavis.